title: Company profile: Aviir, Inc.
abstract: Aviir, Inc. is a venture-funded biotechnology company developing and commercializing laboratory tests to provide personalized information to physicians and patients, with the goal of preventing cardiovascular disease and metabolic syndromes. Leveraging advanced research, Aviir developed and launched MIRISK VP™, a risk assessment test to better identify individuals at risk of a heart attack. Aviir also offers an extensive menu of other cardiovascular and metabolic tests through its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Efforts are likewise focused on expanding genomics testing capability to address sudden cardiac death attributed to inherited cardiovascular diseases. This completes their integrated precision diagnostics approach that combines biomarker immunoassays with genomic and transcription analysis, along with core clinical chemistry to deliver a comprehensive personal health solution.
authors: Aviir, Inc., Irvine, CA 92620, USA. mike.beggs@aviir.com
authors: Michael
authors: M
authors: Beggs
authors: William H
authors: WH
authors: Biggs
authors: Cynthia
authors: C
authors: French
mesh_terms: D015415:Biomarkers / Q000032:analysis; D001709:Biotechnology; D016757:Death, Sudden, Cardiac / Q000209:etiology*; D006801:Humans; D018570:Risk Assessment
chemical_list: D015415:Biomarkers